Business Context and Reporting Period
This Form 8-K, dated July 19, 2017, reports the completion of a transformative business combination for Dare Bioscience, Inc. (formerly Cerulean Pharma Inc.). The filing details the acquisition of Dare Bioscience Operations, Inc. (Dare Operations), a reverse stock split, a corporate name change, and the sale of specific assets to Novartis. The reporting period covers events finalized on July 19, 2017, with the name change and stock split becoming effective on July 20, 2017.
Key Financial Metrics and Transaction Details
- Transaction Type: Reverse acquisition (Dare Operations is the accounting acquirer).
- Stock Issuance: The Company issued 3,154,175 shares of common stock to Dare Operations selling stockholders based on an exchange ratio of approximately 0.203 shares per Dare Operations share.
- Ownership Structure: Post-transaction, former Dare Operations equity holders own approximately 51% of the Company, while pre-transaction Cerulean shareholders own approximately 49%.
- Share Count: Approximately 6,047,200 shares of common stock were outstanding immediately following the transaction and reverse split.
- Reverse Stock Split: A 1-for-10 reverse stock split was executed; fractional shares were settled in cash based on the July 19, 2017 closing price.
- Asset Sale Proceeds: The Company received a cash purchase price of $6,000,000 from Novartis for the sale of its Dynamic Tumor Targeting platform technology.
- Equity Compensation: Replacement options for 10,149 shares were issued to former Dare Operations option holders. New directors received options to purchase 2,200 shares each at $6.56 per share.
Material Changes Versus Prior Period
- Corporate Identity: The Company changed its name from Cerulean Pharma Inc. to Dare Bioscience, Inc. and its ticker symbol from "CERU" to "DARE" on the NASDAQ Capital Market.
- Business Focus: The Company's primary business shifted to that of Dare Operations, a pharmaceutical company focused on women's reproductive health.
- Asset Portfolio: The Company divested its proprietary Dynamic Tumor Targeting platform and related agreements to Novartis, terminating the previous Novartis Collaboration Agreement and ending entitlement to future milestone payments or royalties under that agreement.
- Capital Structure: The 1-for-10 reverse stock split significantly reduced the number of outstanding shares and adjusted the share price.
Guidance, Outlook, and Management Commentary
- Management Changes: A complete change in control occurred. Christopher D.T. Guiffre (CEO) and Gregg Beloff (Interim CFO) resigned. Sabrina Martucci Johnson was appointed President and CEO, and Lisa Walters-Hoffert was appointed CFO.
- Board Composition: The Board was reconstituted with five members, including Roger L. Hawley (Chairman), Susan L. Kelley, William H. Rastetter, Robin J. Steele, and Sabrina Martucci Johnson.
- Compensation Outlook: Current executive salaries are set at $41,600 annually to conserve cash. The Compensation Committee expects to adjust these levels to align with industry practices in the future.
- Financial Reporting: The filing notes that financial statements of the acquired business and pro forma financial information will be filed in an amendment within 71 days. No specific revenue, profit, or cash flow metrics for the current period are provided in this text.
Important Facts for Investor Verification
- Verify the pro forma financial statements to be filed within 71 days to understand the combined entity's liquidity and debt position.
- Confirm the cessation of revenue streams related to the Novartis Collaboration Agreement and the impact of the $6 million asset sale on cash reserves.
- Monitor the future adjustment of executive compensation, which is currently below market rates.
- Review the new CUSIP number (23666P 101) and ticker symbol (DARE) for trading purposes.
- Assess the strategic shift to women's reproductive health products as the sole remaining business focus.